Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Trading 02-05 12:28:59 EST

48.17

+1.00

+2.12%

High48.58	Low47.07	Vol403.20K
Open47.36	D1 Closing47.17	Amplitude3.21%
Mkt Cap5.95B	Tradable Cap5.05B	Total Shares123.55M
T/O19.36M	T/O Rate0.38%	Tradable Shares104.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":48.17,"timestamp":1738776527751,"preClose":47.17,"halted":0,"volume":403196,"delay":0,"floatShares":104773890,"shares":123554612,"eps":-4.219128,"marketStatus":"Trading","change":1,"latestTime":"02-05 12:28:59 EST","open":47.36,"high":48.5828,"low":47.07,"amount":19362144.047732,"amplitude":0.032071,"askPrice":48.17,"askSize":7,"bidPrice":48.13,"bidSize":52,"shortable":3,"etf":0,"ttmEps":-4.219128,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1738789200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":47.17,"preHourTrading":{"tag":"盘前","latestPrice":47.17,"preClose":47.17,"latestTime":"09:28 EST","volume":590,"amount":27833.66123,"timestamp":1738765699815},"postHourTrading":{"tag":"盘后","latestPrice":47.78,"preClose":47.17,"latestTime":"19:02 EST","volume":19553,"amount":922533.96,"timestamp":1738713777128},"volumeRatio":0.427092,"impliedVol":0.7737,"impliedVolPercentile":0.6853},"requestUrl":"/m/hq/s/GH/tweets","defaultTab":"tweets","newsList":[{"id":"2509744999","title":"GH Research 10M share Secondary priced at $15.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2509744999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509744999?lang=en_us&edition=fundamental","pubTime":"2025-02-05 10:25","pubTimestamp":1738722307,"startTime":"0","endTime":"0","summary":"The deal priced below last closing price of $16.32. Cantor Fitzgerald, Stifel and RBC Capital are acting as joint book running managers for the off...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-10m-share-secondary-priced-at-15-00?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-10m-share-secondary-priced-at-15-00?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4196","BK4535","BK4551","GH","BK4585","BK4588"],"gpt_icon":0},{"id":"2509433914","title":"GH Research Announces Pricing of $150 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509433914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509433914?lang=en_us&edition=fundamental","pubTime":"2025-02-05 09:52","pubTimestamp":1738720320,"startTime":"0","endTime":"0","summary":"DUBLIN, Feb.  05, 2025  (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3020875/0/en/GH-Research-Announces-Pricing-of-150-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4535","BK4156","BK4585","GH","BK4196"],"gpt_icon":0},{"id":"2508031461","title":"Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508031461","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508031461?lang=en_us&edition=fundamental","pubTime":"2025-02-04 09:22","pubTimestamp":1738632123,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where GH Research PLC  stands against the other healthcare stocks.The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI. The healthcare sector was a hot topic during the Stargate project announcement, so it is likely that there are going to be even more breakthroughs here as technology advances.The S&P 500 Healthcare Index trailed the broader market considerably in the past few years. However, it has risen 7% year-to-date so far. There are many promising drugs awaiting approvals and trials right now. As such, healthcare EBITDA is projected to grow at a 7% CAGR, reaching $987 billion by 2028.Overall GHRS ranks 2nd on our list of the healthcare stocks that are skyrocketing so far in 2025. While we acknowledge the potential of GHRS as an investment, our convic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-gh-research-plc-ghrs-012203288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GH","QQQ","TQQQ","PSQ",".IXIC","QID","BK4196","NVIW.SI","NQmain","USJW.SI","MNQmain","BK4585","GHRS","QLD","SQQQ","BK4551","BK4588","BK4535","BK4539","TSYW.SI","BK4007","USAW.SI"],"gpt_icon":0},{"id":"2508176146","title":"GH Research Launches $150 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508176146","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508176146?lang=en_us&edition=fundamental","pubTime":"2025-02-04 06:16","pubTimestamp":1738620996,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) said late Monday it has launched an underwritten public offering of $150 million of shares.The company said it plans to grant its underwriters an option to acquire up to $22.5 million of additional shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GH","BK4539","BK4585","BK4588","BK4551","GHRS","BK4535","BK4196","BK4007"],"gpt_icon":0},{"id":"2508176351","title":"GH Research Initiates $150 Million Public Offering to Advance Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2508176351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508176351?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:49","pubTimestamp":1738619388,"startTime":"0","endTime":"0","summary":"GH Research ( ($GHRS) ) has issued an update. On February 3, 2025, GH Research PLC announced the launch of a public offering in the U.S. to raise $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-initiates-150-million-public-offering-to-advance-depression-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-initiates-150-million-public-offering-to-advance-depression-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4535","BK4585","BK4551","BK4196","BK4588"],"gpt_icon":0},{"id":"2508173556","title":"GH Research announces $150M ordinary shares offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508173556","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508173556?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:12","pubTimestamp":1738617167,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) announced the commencement of an underwritten public offering of $150M of ordinary shares. All of the ordinary shares are to be ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-announces-150m-ordinary-shares-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-announces-150m-ordinary-shares-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4535","BK4585","BK4539","BK4007","BK4551","GHRS","BK4196","BK4588"],"gpt_icon":0},{"id":"2508717867","title":"GH Research Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508717867","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508717867?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:03","pubTimestamp":1738616580,"startTime":"0","endTime":"0","summary":"DUBLIN, Feb.  03, 2025  (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019846/0/en/GH-Research-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4156","BK4588","BK4585","GH","BK4551","BK4535"],"gpt_icon":0},{"id":"2508124749","title":"JMP Securities Reaffirms Their Buy Rating on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508124749","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508124749?lang=en_us&edition=fundamental","pubTime":"2025-02-04 03:15","pubTimestamp":1738610116,"startTime":"0","endTime":"0","summary":"In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-buy-rating-on-gh-research-ghrs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-buy-rating-on-gh-research-ghrs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","GHRS","GH"],"gpt_icon":0},{"id":"2508144212","title":"GH Research Shares Jump After Positive Phase 2B Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144212","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508144212?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:58","pubTimestamp":1738594680,"startTime":"0","endTime":"0","summary":"GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression.The Dublin-based biopharmaceutical company said the trial recruited 81 patients with TRD, with 40 patients receiving GH001 and 41 receiving placebo.Psychotherapeutic intervention wasn't a component of either part of this trial, said the company.GH said GH001 led to a significant reduction of patients on the Montgomery-Asberg Depression Rating Scale compared with the placebo group.All secondary endpoints in the trial were met, with results consistent with the primary endpoint, the company said.GH001 was well-tolerated and no serious adverse events were reported in the double-blind part of the trial, and all treatment emergent adverse events were mild or moderate with no severe adverse events observed, said GH. There was no evidence of treatment-emergent suicidal id","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","BK4196","BK4588","BK4585","BK4539","BK4535","GH","BK4007","BK4551"],"gpt_icon":0},{"id":"2508170471","title":"GH Research’s GH001 Shows Promising Results in TRD Phase 2b Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508170471","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508170471?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:44","pubTimestamp":1738586641,"startTime":"0","endTime":"0","summary":"An announcement from GH Research ( ($GHRS) ) is now available. On February 3, 2025, GH Research PLC announced that their Phase 2b clinical trial fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-researchs-gh001-shows-promising-results-in-trd-phase-2b-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-researchs-gh001-shows-promising-results-in-trd-phase-2b-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","GH","BK4535","BK4585","BK4588","BK4551"],"gpt_icon":0},{"id":"2508117863","title":"GH Research Shares Soar 90% Pre-Bell After Trial of GH001 to Treat Depression Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2508117863","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508117863?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:28","pubTimestamp":1738585680,"startTime":"0","endTime":"0","summary":"GH Research  shares were soaring over 90% in Monday's premarket session after it said a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.The biopharmaceutical company also said all secondary endpoints were met and that GH001 was well tolerated with no serious adverse events reported in the double-blind part of the trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","GH","BK4585","BK4551","BK4535","BK4539","BK4196","BK4007","GHRS"],"gpt_icon":0},{"id":"2508112397","title":"GH Research announces primary endpoint met in Phase 2b trial of GH001","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112397","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112397?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:06","pubTimestamp":1738584380,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-announces-primary-endpoint-met-in-phase-2b-trial-of-gh001?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-announces-primary-endpoint-met-in-phase-2b-trial-of-gh001?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","GHRS","BK4007","BK4196","GH","BK4585","BK4551","BK4539","BK4588"],"gpt_icon":0},{"id":"2508311258","title":"GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2508311258","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508311258?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019385/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2508156664","title":"Why Guardant Health, Inc. (GH) Is Among the Best Booming Stocks to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2508156664","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508156664?lang=en_us&edition=fundamental","pubTime":"2025-02-03 05:27","pubTimestamp":1738531620,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Booming Stocks to Invest in Now.In this article, we are going to take a look at where Guardant Health, Inc.  stands against other best booming stocks to invest in now.The U.S. stock market closed on a downbeat on Friday, January 31, as investors grappled with the announcement that President Donald Trump’s new tariffs on major trading partners would take effect the following day. The Dow Jones Industrial Average tumbled 0.75%, to close at 44,544.66 and the S&P 500 shed 0.50% to close at 6,040.53, while the Nasdaq Composite slipped 0.28% to 19,627.44. However, the day marked the end of a tumultuous January for traders with the three major averages still managing to post monthly gains. The S&P 500 rose 2.7%, the Nasdaq advanced 1.6%, and the Dow surged 4.7%.Dimon further discussed the challenges of implementing growth strategies, emphasizing that while many recognize the need for cha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-guardant-health-inc-gh-212700771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","QLD",".IXIC","MNQmain","QID","SQQQ","GH","BK4535","BK4551","BK4588","NVIW.SI","BK4196","TQQQ","TSYW.SI","USAW.SI","USJW.SI","PSQ","NQmain"],"gpt_icon":1},{"id":"2508913784","title":"GH Research Shares Rise Ahead of Release of Clinical-Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2508913784","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508913784?lang=en_us&edition=fundamental","pubTime":"2025-02-01 06:43","pubTimestamp":1738363380,"startTime":"0","endTime":"0","summary":"Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","BK4196","GH","BK4535","BK4585","BK4551","BK4539","BK4588","BK4007"],"gpt_icon":0},{"id":"2508744990","title":"GH Research to Update on Promising TRD Treatment Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508744990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508744990?lang=en_us&edition=fundamental","pubTime":"2025-02-01 05:27","pubTimestamp":1738358833,"startTime":"0","endTime":"0","summary":"GH Research ( ($GHRS) ) just unveiled an update. On January 31, 2025, GH Research PLC announced a forthcoming update on its Phase 2b trial for GH00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-update-on-promising-trd-treatment-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-update-on-promising-trd-treatment-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","GH","BK4535","BK4551","BK4588","BK4196"],"gpt_icon":0},{"id":"2508990803","title":"GH Research to Provide Update on Phase 2b Trial with GH001 in TRD","url":"https://stock-news.laohu8.com/highlight/detail?id=2508990803","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508990803?lang=en_us&edition=fundamental","pubTime":"2025-02-01 05:01","pubTimestamp":1738357260,"startTime":"0","endTime":"0","summary":"DUBLIN, Jan.  31, 2025  (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/31/3019013/0/en/GH-Research-to-Provide-Update-on-Phase-2b-Trial-with-GH001-in-TRD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4551","BK4585","BK4535","BK4196","GH"],"gpt_icon":0},{"id":"2507603269","title":"Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507603269","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507603269?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:05","pubTimestamp":1738271100,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., January 30, 2025----Guardant Health, Inc. , a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-report-fourth-quarter-210500186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","GH","BK4535","BK4585","BK4551","BK4588"],"gpt_icon":0},{"id":"2507627111","title":"Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2507627111","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507627111?lang=en_us&edition=fundamental","pubTime":"2025-01-30 23:44","pubTimestamp":1738251853,"startTime":"0","endTime":"0","summary":"Guardant Health  said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42 healthcare system, the company said.The Shield test will be included in Abu Dhabi Public Health Center's IFHAS screening program and will be offered at facilities run by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region, Guardant added.Organizers expect the program to screen roughly 10,000 individuals during its first year, according to the oncology company.Financial details were not disclosed.Shares of the company were up about 3.7% in recent trading.Price: 49.43, Change: +1.78, Percent Change: +3.74","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","BK4551","BK4585","GH","BK4535","BK4588"],"gpt_icon":0},{"id":"2507162061","title":"These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2507162061","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507162061?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:00","pubTimestamp":1738245610,"startTime":"0","endTime":"0","summary":"Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure helps cut through all the noise.Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.The final step today is to look at a stock that meets our ESP qualifications. Bristol Myers Squibb  earns a Zacks Rank #3 seven days from its next quarterly earnings release on February 6, 2025, and its Most Accurate Estimate comes in at $1.47 a share.Bristol Myers Squibb Company  : Free Stock Analysis Report. Guardant Health, Inc.  : Free Stock Analysis Report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2-medical-stocks-could-beat-140010515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMY","GH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":0.3972},{"period":"3month","weight":0.8652},{"period":"6month","weight":0.5583},{"period":"1year","weight":1.2156},{"period":"ytd","weight":0.544}],"compareEarnings":[{"period":"1week","weight":-0.0045},{"period":"1month","weight":0.0166},{"period":"3month","weight":0.0182},{"period":"6month","weight":0.134},{"period":"1year","weight":0.2218},{"period":"ytd","weight":0.0268}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.064605},{"month":2,"riseRate":0.428571,"avgChangeRate":0.078308},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027891},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.038707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.099696},{"month":6,"riseRate":0.666667,"avgChangeRate":0.048686},{"month":7,"riseRate":0.833333,"avgChangeRate":0.095469},{"month":8,"riseRate":0.5,"avgChangeRate":-0.010162},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.064584},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.046039},{"month":11,"riseRate":0.714286,"avgChangeRate":0.125409},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.067723}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}